China's medical products administrator approved Hutchmed's (HKG:0013) supplemental new drug application for its savolitinib drug for a type of locally advanced or metastatic non-small cell lung cancer, according to a Tuesday filing with the Hong Kong Exchange.
The drug, branded Orpathys, is indicated for non-small cell lung cancer with MET exon 14 skipping alteration mutation, which is seen in patients over 70 years old.
China also converted the conditional approval for Orpathys into a full one, the filing said.
Shares closed 3% higher in Hong Kong during Tuesday's trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.